October 23, 2008

October 23, 2009

1.0 Hour

In the United States, human papilllomavirus (HPV) is the most common newly acquired sexually transmitted infection, with an estimated annual incidence of 6.2 million cases. The 2 most common high-risk (ie, oncogenic) types, HPV 16 and 18, cause 70% of all cervical cancers, as well as other anogenital and some oropharyngeal cancers. The 2 most common low-risk HPV types, 6 and 11, cause low-grade cervical dysplasias, genital warts, and recurrent respiratory papillomatosis. A quadrivalent HPV vaccine that protects aginst HPV types 6, 11, 16, and 18 has been approved by the US Food and Drug Administration (FDA), and a bivalent HPV vaccine that protects against HPV types 16 and 18 remains under FDA review. Emerging research indicates that HPV vaccination may provide expanded benefits, including cross-protection against nonvaccine high-risk HPV types and efficacy in women 24 to 45 years of age. Studies are ongoing to assess efficacy in the male population.

This activity will review the burden of HPV-related disease, the latest clinical data on HPV vaccines, and the expected public health benefits of widespread HPV vaccination. Additionally, an expert roundtable discussion will address questions frequently asked by health care providers and patients regarding HPV vaccination.

This activity has been designed to meet the educational needs of family physicians, pediatricians, gynecologists, and other health care professionals who wish to learn more about preventing cervical cancer and other HPV-related diseases.

At the conclusion of this educational activity, participants should be better able to:

• Review the health burden of HPV-related disease
• Summarize the latest safety and efficacy data for the HPV vaccines
• Evaluate the expected public health benefits of widespread HPV vaccination
• Address the most frequently asked questions regarding HPV vaccination

Kevin A. Ault, MD (Activity Co-Chairperson)
Associate Professor
Division of Gynecologic Oncology
Department of Gynecology and Obstetrics
Emory University School of Medicine
Atlanta, Georgia

Anna R. Giuliano, PhD (Activity Co-Chairperson)
Professor and Program Leader
Risk Assessment, Detection, and Intervention Program
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Darron R. Brown, MD
Professor of Medicine, Microbiology, and Immunology
Indiana University School of Medicine
Indianapolis, Indiana

Patti E. Gravitt, MS, PhD
Assistant Professor
Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland

S. Paige Hertweck, MD
Associate Professor
Department of Obstetrics, Gynecology, and Women's Health
University of Louisville School of Medicine
Louisville, Kentucky

Warner K. Huh, MD
Associate Professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

Edward John Mayeaux, Jr, MD, DABFP, FAAFP
Professor of Family Medicine
Professor of Obstetrics and Gynecology
Associate Family Practice Residency Program Director
Department of Family Medicine
Louisiana State University Health Sciences Center School of Medicine in Shreveport
Shreveport, Louisiana

Joel M. Palefsky, MD
Professor of Medicine
Associate Dean for Clinical and Translational Research
Co-Director, UCSF Clinical and Translational Sciences Institute
University of California, San Francisco
San Francisco, California

Mark Spitzer, MD
Chairman and Residency Program Director
Department of Obstetrics and Gynecology
Brookdale University Hospital and Medical Center
Brooklyn, New York
Professor of Clinical Obstetrics and Gynecology
Weill Medical College of Cornell University
New York, New York

SciMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicans.

SciMed designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

There are no fees for participating in and receiving CME credit for this activity. In order to obtain CME credit for participating in this activity during the period September 1, 2008 through September 1, 2009, participants must 1) read the educational objectives and disclosure statements; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question; 4) complete the evaluation form; 5) submit the evaluation form with posttest online.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 80% or better.

SciMed assesses conflicts of interest with its faculty and all individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are resolved by SciMed to ensure fair balance and scientific objectivity.

When asked to report any potential conflict(s) of interest, faculty reported the following:

Kevin A. Ault, MD
Grants/Research Support: Gen-Probe, Merck & Co., Inc., National Institute of Allergy and Infectious Diseases
Consultant: Merck & Co., Inc.
Policy Committees: Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases

Darron R. Brown, MD
Grants/Research Support: Merck & Co., Inc.
Consultant: Merck & Co., Inc.
Speakers Bureau: Merck & Co., Inc.
Other: Indiana University and Merck & Co., Inc. have a confidential agreement related to intellectual property that pays the University based on certain landmarks regarding the HPV vaccine. Dr. Brown receives a portion of these structured payments as income.

Anna R. Giuliano, PhD
Grants/Research Support: Merck & Co., Inc.
Consultant: Merck & Co., Inc.
Speakers Bureau: Merck & Co., Inc.

Patti E. Gravitt, MS, PhD
Grants/Research Support: Merck & Co., Inc., Roche Molecular Systems
Consultant: Merck & Co., Inc., Roche Molecular Systems
Speakers Bureau: Merck & Co., Inc.

S. Paige Hertweck, MD
Grants/Research Support: Barr Laboratories
Consultant: Merck & Co., Inc.
Speakers Bureau: Merck & Co., Inc.

Warner K. Huh, MD
Grants/Research Support: Cytyc Corporation, GlaxoSmithKline, Merck & Co., Inc., MGI PHARMA, Roche Pharmaceuticals, Takeda Pharmaceuticals Inc., Tigris Pharmaceuticals
Consultant: GlaxoSmithKline, Merck & Co., Inc., MGI PHARMA, Nventa Biopharmaceuticals Corporation, Roche Pharmaceuticals, Takeda Pharmaceuticals Inc. 
Speakers Bureau: Cytyc Corporation, Digene Corporation, Merck & Co., Inc.

Edward John Mayeaux, Jr, MD, DABFP, FAAFP
Advisory Board: GlaxoSmithKline, Merck & Co., Inc.
Speakers Bureau: Merck & Co., Inc.

Joel M. Palefsky, MD
Grants/Research Support: Merck & Co., Inc.

Mark Spitzer, MD
Consultant: Merck & Co., Inc.
Speakers Bureau: Merck & Co., Inc.

All SciMed personnel involved in the development of content for this activity have no relevant conflicts to report.

The materials for this activity were peer reviewed by J. Dennis Fortenberry, MD, MS, Professor, Indiana University School of Medicine. Dr. Fortenberry has no relevant conflicts to report.

The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of SciMed or the commercial supporter. Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product, device, or procedure mentioned.

SciMed
420 Lexington Avenue
Suite 902
New York, NY 10170
www.scimedny.com

For more information regarding the prevention of cervical cancer and other HPV-related diseases, please visit www.hpvcme.org